CORESTEMCHEMON Inc. Logo

CORESTEMCHEMON Inc.

Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.

166480 | KO

Overview

Corporate Details

ISIN(s):
KR7166480004
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로255번길 24 (삼평동), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CORESTEMCHEMON Inc. is a biotechnology corporation operating through two primary divisions: Bio-pharmaceuticals and a Nonclinical Contract Research Organization (CRO). The Bio-pharmaceutical division focuses on developing novel stem cell therapies for intractable conditions, with clinical trials targeting neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), multiple sclerosis, and cerebellar ataxia, as well as autoimmune disorders such as systemic lupus erythematosus (SLE). The Nonclinical CRO division provides essential preclinical services, conducting toxicity and efficacy evaluations for a wide range of clients in the pharmaceutical, biopharmaceutical, medical device, and cosmetic industries.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 00:00
Share Issue/Capital Change
유상증자1차발행가액결정 (주주배정후 실권주 일반공모)
Korean 8.6 KB
2025-09-16 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 38.9 KB
2025-09-16 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 291.4 KB
2025-09-16 00:00
Prospectus
투자설명서
Korean 3.3 MB
2025-09-16 00:00
Share Issue/Capital Change
권리락 (유상증자)
Korean 3.5 KB
2025-09-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 44.4 KB
2025-09-08 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.10)
Korean 3.5 MB
2025-09-01 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.10)
Korean 3.8 MB
2025-08-18 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 35.4 KB
2025-08-18 00:00
Registration Form
증권신고서(지분증권) (2025.10)
Korean 3.2 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.0 MB
2025-08-08 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.4 MB
2025-07-28 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 21.4 KB
2025-07-21 00:00
Capital/Financing Update
교환사채(해외교환사채포함)발행후만기전사채취득 (제2회차)
Korean 9.9 KB
2025-07-21 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 30.8 KB

Automate Your Workflow. Get a real-time feed of all CORESTEMCHEMON Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CORESTEMCHEMON Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CORESTEMCHEMON Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America
PBH
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America
PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea
296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America
PROK
ProMIS Neurosciences Inc. Logo
Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.
United States of America
PMN
Propanc Biopharma, Inc. Logo
Developing proenzyme therapies to prevent solid tumor recurrence and metastasis.
United States of America
PPCB
ProQR Therapeutics N.V. Logo
Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.
United States of America
PRQR
Protagenic Therapeutics, Inc.\new Logo
Developing novel peptide drugs to treat stress-related neuropsychiatric & CNS disorders.
United States of America
PTIX
Protagonist Therapeutics, Inc Logo
Develops peptide therapeutics for blood disorders and inflammatory or immunomodulatory diseases.
United States of America
PTGX
Protalix BioTherapeutics, Inc. Logo
Develops plant-cell-based protein therapies for rare diseases like Gaucher and Fabry.
United States of America
PLX

Talk to a Data Expert

Have a question? We'll get back to you promptly.